Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4.6% - Here's Why

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) shares fell 4.6% during trading on Friday . The stock traded as low as $29.71 and last traded at $29.35. 12,364 shares changed hands during trading, a decline of 83% from the average session volume of 74,330 shares. The stock had previously closed at $30.78.Get Lyell Immunopharma alerts:Wall Street Analysts Forecast GrowthSeveral equities research analysts have commented on LYEL shares. HC Wainwright raised shares of Lyell Immunopharma from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $20.00 to $45.00 in a research report on Tuesday, December 9th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Lyell Immunopharma in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Lyell Immunopharma presently has an average rating of "Hold" and a consensus target price of $45.00.Check Out Our Latest Research Report on Lyell ImmunopharmaLyell Immunopharma Stock Down 10.8%The business has a fifty day moving average of $24.65 and a 200 day moving average of $16.53. The firm has a market cap of $583.14 million, a P/E ratio of -1.19 and a beta of -0.14. Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.81) by $0.68. The company had revenue of $0.02 million during the quarter, compared to analysts' expectations of $0.01 million. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%. Research analysts expect that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year. Hedge Funds Weigh In On Lyell ImmunopharmaLarge investors have recently modified their holdings of the stock. Millennium Management LLC boosted its holdings in shares of Lyell Immunopharma by 140.0% during the 3rd quarter. Millennium Management LLC now owns 125,361 shares of the company's stock worth $2,036,000 after buying an additional 73,132 shares during the period. Foresite Capital Management V LLC raised its holdings in Lyell Immunopharma by 17.3% in the 3rd quarter. Foresite Capital Management V LLC now owns 477,078 shares of the company's stock valued at $7,748,000 after acquiring an additional 70,426 shares during the period. ARCH Venture Management LLC lifted its position in Lyell Immunopharma by 51.5% during the third quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company's stock worth $44,807,000 after acquiring an additional 938,438 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Lyell Immunopharma by 107.0% during the third quarter. Two Sigma Investments LP now owns 20,827 shares of the company's stock worth $338,000 after acquiring an additional 10,768 shares during the period. Finally, Takeda Pharmaceutical Co. Ltd. grew its position in shares of Lyell Immunopharma by 33.3% in the third quarter. Takeda Pharmaceutical Co. Ltd. now owns 54,887 shares of the company's stock valued at $891,000 after purchasing an additional 13,722 shares during the last quarter. 66.05% of the stock is owned by institutional investors. Lyell Immunopharma Company Profile (Get Free Report)Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company's approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment. The company's pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.Further ReadingFive stocks we like better than Lyell ImmunopharmaBuy this $2 Gold Stock Before January 1, 2026ALERT: Drop these 5 stocks before January 2026!Bombshell Exposé on China StrikesDo not delete, read immediatelyBNZI Posts Record Q3 Revenue – See What’s Driving It.This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Lyell Immunopharma Right Now?Before you consider Lyell Immunopharma, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.While Lyell Immunopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here